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INTRODUCTION
Nutritional status remains suboptimal in patients with cystic fibrosis (CF) and pancreatic insufficiency (PI) despite effort to optimize pancreatic enzymes and diets [1] [2] [3] . Chronic steatorrhea results in loss of fat calories and fat soluble vitamins [4] [5] [6] [7] , and stool coefficient of fat absorption (CFA) often ranges from 81 to 85% [8] [9] [10] . In a recent study of over 200 patients, those with CFA < 85% had growth faltering 6 . Essential fatty acid insufficiency has been associated with poorer growth and pulmonary function, and is in part a consequence of chronic fat malabsorption 9, [11] [12] [13] [14] [15] [16] [17] [18] .
Second generation LYM-X-SORB TM (LXS) (BioMolecular Products, Byfield, MA; Avanti Polar Lipids, Alabaster, AL) 19 , with enhanced taste and mixability is a phospholipid-and triglyceriderich matrix. The aim of this randomized placebo-controlled double-blinded trial was to evaluate the efficacy of 12-month supplementation with LXS to improve fat absorption indicated by plasma fatty acid (FA) concentrations and stool CFA.
METHODS
Subjects aged 5.0 to 17.9 years with CF, PI and mild to moderate lung disease were recruited from ten CF Centers. LXS is composed of lysophosphatidylcholine, triglycerides and FA which form an organized lipid matrix complexed to wheat flour and sugar. Subjects aged 5.0-11.9 years received two packets/day, and subjects aged 12.0-17.9 years received three packets/day. The placebo had similar calories (~150 kcal/packet), total fat, FA and macronutrient distribution. The inclusion/exclusion criteria, study design and method details, LXS composition, and the results for LXS impact on choline status have been previously reported 10, 20, 21 .
Dietary intake was assessed using 3-day weighed records 22, 23 . A 72-hour stool sample was collected and total fat content determined (Mayo Medical Laboratories, Rochester, MN), and CFA calculated 8 . Daily pancreatic enzyme medication use was determined. Subjects completed the Pediatric Quality of Life Inventory (PedsQL 4.0) 24 , and Cystic Fibrosis Questionnaire-Revised (CFQ-R) 25, 26 .
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Quantitation of morning fasting plasma FA was performed in two steps: 1) acid-base hydrolysis; 2) hexane extraction/derivatization with pentafluorobenzyl bromide (Mayo Medical Laboratories). Separation/detection was accomplished by capillary gas chromatography electroncapture negative ion-mass spectrometry, with quantitation based on analysis in selected ionmonitoring mode using 13 stable isotope-labeled internal standards 27 .
Descriptive statistics were presented as frequency counts and percentages for categorical variables and mean ± standard deviation (SD) for continuous variables. Two-sample t-test 
RESULTS
There were 110 subjects recruited, 56 randomized to placebo and 54 to LXS supplementation. Subjects (10.4±3.0 years), were 57% male, 57% ΔF508 homozygous, and had mild pulmonary disease (FEV 1 : 95±23 % predicted), suboptimal growth status (height-for-age Z Copyright © ESPGHAN and NASPGHAN. All rights reserved.
score: -0.4±0.9; weight-for-age Z score (WAZ): -0.4±0.8; BMI-for-age Z score (BMIZ):
-0.2±0.8), and moderate fat malabsorption (CFA: 83±12%). The overall quality of life score (PedsQL) was 82±12 for parent-assessed and 81±13 for the child-assessed measures. The randomization groups did not differ at baseline for any measure.
Twenty-four subjects after baseline (10 placebo, 14 LXS) and 16 subjects after 3 months (7 placebo, 9 LXS) withdrew from the study. Neither the attrition rate nor the reasons for dropping out differed by randomization group 29 Change in LA in subjects whose baseline LA was in the lowest quartile range for this sample (≤ 1920 umol/L) was analyzed (10 in placebo and 17 in LXS group). These subjects had lower BMI at baseline compared to the other quartiles combined (-0.48±0.82 vs. -0.11±0.73;
P=0.03). LA increased significantly in LXS group from baseline to 3 and 12 months (1640±198
to 1936±392 and 2120±580 nmol/mL, respectively, P≤0.002). No significant change in LA occurred in placebo group (1693±184 to 1806±429 and 1752±332 nmol/mL, respectively). LA change over time between LXS and placebo was significant at 12 months (R×T, P 0-12 = 0.038).
We have previously reported that both LXS and placebo were safe 10, 29 , and growth status improved in both groups 10, 21 . Quality of life score indicated by the PedsQL or CFQ-R did not change and there were no differences by randomization group. When the groups combined, there were significant increases from baseline to 12 months in child-assessed emotional triglycerides to identify fat sources that would enhance absorption in CF and PI. They concluded that both long-term adequate calories as well as supplemental LA were necessary to prevent essential FA deficiency, with optimized pancreatic enzyme replacement. A number of studies to improve LA status with different designs and different LA sources have been conducted more recently [32] [33] [34] [35] [36] [37] , none of which offered LA in a more readily absorbable form. In our CF study, baseline dietary intake of LA was 159% of recommendation for healthy people (~18g/day).
Both LXS and placebo supplements contained a small amount of LA, and daily intake increased about 15% (to 21 g) in both groups. Only the LXS group showed a significant increase in the fasting plasma LA, and particularly among those with the lowest baseline LA concentrations.
These findings indicate that the unique LXS lipid structure and composition resulted in improved LA absorption efficiency.
The more frequently described FA abnormalities in CF include low LA, docosahexaenoic acid (DHA), PUFA, and high T:T ratios [13] [14] [15] . Few subjects in the current study had baseline LA concentrations below laboratory reference range. However, over 1/3 had essential FA insufficiency based upon the laboratory reference range for the T:T ratio. It is notable, however, that for subjects more at-risk for LA insufficiency at baseline (LA ≤1920 umol/L), LA concentrations increased by 29% over 12 months in LXS with no change in placebo group. The proportion of subjects with EFA insufficiency based upon the T:T ratio declined significantly from 41% at baseline to 26% after 12 months, with no group difference. This was expected for the LXS group with improved absorption of multiple FAs, but the reason for this improvement in the placebo group was less clear. Perhaps the additional dietary energy, FA and LA in either LXS or placebo supported change in this ratio. It should be noted that this ratio method was developed before reliable actual measurement of plasma LA was clinically available to detect this specific essential FA deficiency.
LA deficiency has clinical consequences including impaired growth, wound healing, and seborrheic dermatitis 38 . In addition to PI and fat malabsorption 5, 39 , plasma FA abnormalities may relate to increased energy expenditure, increased oxidative stress 40, 41 , increased cell membrane turnover 42 , abnormal release of FA from the cell membrane 43 , and defects related to specific CF genotypes 12, 44 . Suboptimal FA status has been associated with poorer pulmonary and growth outcomes in CF 13, 45, 46 . suggesting that the improved weight status observed in both randomization groups was psychosocially beneficial, though this requires further examination.
Study strengths included a study design that supports generalizability with enrollment from 10 CF Centers, successful randomization, and good adherence. Limitations include subject attrition that may have introduced bias, however, there was no evidence that dropouts and completers differed at baseline in demographic, clinical outcome measures, or plasma FA status.
Reasons for dropping out did not differ by randomization groups. The study design did not include either a CF or a non-CF, non-intervention group for comparison. The dose of LXS was based on a prior study with LXS in which increased FA concentrations were observed. A higher dose may have a different effect on the outcomes of interest.
In summary, LXS treatment improved dietary fat absorption compared to placebo as indicated by plasma FA, LA and CFA in children with CF and PI who had similar intake of energy, fats and LA, and less pancreatic enzyme medication use. Increased total FA and LA Copyright © ESPGHAN and NASPGHAN. All rights reserved.
absorption may support better growth status in school aged children. Based on these results and clinical experience, LXS has potential to reduce fat malabsorption in CF clinical care. Further investigation is needed to evaluate the effectiveness of LXS to reduce fat malabsorption and treat or prevent malnutrition in patients with other diagnoses.
